Mirum Pharmaceuticals, Inc. (MIRM) Tops Q1 EPS by 17c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. FIX
9. TSCO
10. BE

Go back to Mirum Pharmaceuticals, Inc. (MIRM) Tops Q1 EPS by 17c

Mirum Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update

May 5, 2022 8:00 AM EDT

- Total revenue for the first quarter of 2022 was $12.9 million including net product revenue for LIVMARLI® (maralixibat) oral solution of $10.9 million.

- Conference call to provide business updates today, May 5 at 5:30 a.m. PT/8:30 a.m. ET

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the first quarter ended March 31, 2022 and provided a business update.

The first quarter was tremendously successful for Mirum. Rapid growth in LIVMARLI revenue means that children suffering from pruritus associated with... More